1.77
0.04 (2.31%)
| Previous Close | 1.73 |
| Open | 1.74 |
| Volume | 2,328,048 |
| Avg. Volume (3M) | 1,984,991 |
| Market Cap | 658,898,432 |
| Price / Sales | 2.45 |
| Price / Book | 0.970 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -79.62% |
| Operating Margin (TTM) | -29.42% |
| Diluted EPS (TTM) | -0.520 |
| Quarterly Revenue Growth (YOY) | -14.20% |
| Total Debt/Equity (MRQ) | 118.03% |
| Current Ratio (MRQ) | 5.70 |
| Operating Cash Flow (TTM) | -143.45 M |
| Levered Free Cash Flow (TTM) | -71.55 M |
| Return on Assets (TTM) | -18.01% |
| Return on Equity (TTM) | -43.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Standard BioTools Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.17 |
|
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 1.86% |
| % Held by Institutions | 73.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hollow Brook Wealth Management Llc | 30 Sep 2024 | 5,532,951 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Feb 2025 | Announcement | Standard BioTools to Participate in Upcoming Investor Conferences |
| 26 Feb 2025 | Announcement | Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results |
| 12 Feb 2025 | Announcement | Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 |
| 13 Jan 2025 | Announcement | Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue |
| 08 Jan 2025 | Announcement | Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |